1. Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1 + PD1 + CD8 + T cell differentiation.
- Author
-
Zhou W, Qu M, Yue Y, Zhong Z, Nan K, Sun X, Wu Q, Zhang J, Chen W, and Miao C
- Subjects
- Animals, Mice, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Humans, Cell Line, Tumor, Mice, Inbred C57BL, Drug Synergism, Colorectal Neoplasms pathology, Colorectal Neoplasms drug therapy, Colorectal Neoplasms immunology, Colorectal Neoplasms metabolism, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes drug effects, Cell Differentiation drug effects, Programmed Cell Death 1 Receptor metabolism, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor immunology, Acetylcysteine pharmacology, Hepatocyte Nuclear Factor 1-alpha metabolism, Hepatocyte Nuclear Factor 1-alpha genetics, Disease Progression
- Abstract
Background: Programmed cell death protein 1 (PD-1) blockade is essential in treating progressive colorectal cancer (CRC). However, some patients with CRC do not respond well to immunotherapy, possibly due to the exhaustion of CD8
+ T cells in the tumor microenvironment. N-Acetylcysteine (NAC) can reduce CD8+ T cell exhaustion in vitro and induce their differentiation into long-lasting phenotypes, thus enhancing the anti-tumor effect of adoptive T cell transfer. However, whether NAC can be combined with PD-1 blockade in CRC treatment and how NAC regulates CD8+ T cell differentiation remain unclear. Hence, in this study, we aimed to investigate whether NAC has a synergistic effect with PD-1 blockers against CRC progression., Methods: We constructed a mouse CRC model to study the effect of NAC on tumors. The effect of NAC on CD8 + T cell differentiation and its potential mechanism were explored using cell flow assay and other studies in vitro and ex vivo., Results: We demonstrated that NAC synergized PD-1 antibodies to inhibit CRC progression in a mouse CRC model mediated by CD8+ T cells. We further found that NAC can induce TCF1+ PD1+ CD8+ T cell differentiation and reduce the formation of exhausted T cells in vitro and in vivo. Moreover, NAC enhanced the expression of Glut4 in CD8+ T cells, promoting the differentiation of TCF1+ PD1+ CD8+ T cells., Conclusions: Our study provides a novel idea for immunotherapy for clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8+ T cell differentiation., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF